Legal, Regulatory, and Business Intelligence Hub
With GLP-1 medications like semaglutide and tirzepatide now widely used for weight loss management, the legal, regulatory, and business challenges surrounding their use, particularly in 503A compounding, have become increasingly complex. Frier Levitt attorneys are at the forefront of this evolving landscape, providing critical insights for pharmacies, prescribers, and other stakeholders navigating this dynamic landscape.
This resource hub features our latest webinars and articles covering FDA guidance, reimbursement strategies, payer trends, state board enforcement, litigation risks, and compliance strategies to help you stay informed and compliant amid rapidly evolving developments in the GLP-1 space.
Featured Articles
- Trump Administration’s Proposed Peptide Enforcement Discretion Policy: What Compounding Pharmacies and Peptide Suppliers Need to Know – October 14, 2026
The Trump administration is reportedly considering a significant change in the federal government’s approach to peptide compounding. According to recent reports, the administration is exploring an interim enforcement discretion policy… - FDA Warning Letter Signals New Enforcement Theory for Compounded GLP-1 Combination Products – September 25, 2026
The U.S. Food and Drug Administration (FDA) issued a Warning Letter to Empower Clinic Services, LLC (dba Empower Pharmacy) addressing its compounding of tirzepatide and semaglutide combination products… - Lilly’s Retatrutide Lawsuits: A New Enforcement Playbook
– August 18, 2026
Eli Lilly and Company (“Lilly”) filed six federal lawsuits on August 12, 2026, against businesses it accuses of illegally selling retatrutide, the company’s experimental “triple-agonist” obesity drug that has not yet been approved by the U.S. Food and Drug Administration (FDA) or any other regulator worldwide…
Featured Webinars
- The Fast and the Formulated: Navigating FDA Enforcement, GLP-1s, Peptides, and Emerging Business Models – August 20, 2026
Pharmacy compounding remains one of the most closely watched areas of FDA enforcement, particularly as compounded GLP-1s and peptides continue to draw regulatory and manufacturer attention… - Legal Insights into GLP-1 and Peptide Compounding in 2026 – March 18, 2026
As GLP-1 medications and peptide therapies continue to face heightened regulatory scrutiny, pharmacies and telehealth providers must navigate a rapidly shifting enforcement landscape… - Mastering GLP-1 Compounding Series Q&A Roundup – September 13, 2025
Frier Levitt’s healthcare and pharmacy law attorneys present a follow-up webinar tackling key issues based on the most pressing questions from our GLP-1 Compounding Series…
Meet Our Team
Edgar J. Asebey
Partner
973-852-8392
easebey@frierlevitt.com
Jesse C. Dresser
Partner
973-852-8361
jdresser@frierlevitt.com
Winston S. Kirton
Partner, Chair of FDA Practice
973-852-1871
wkirton@frierlevitt.com
Arielle T. Miliambro
Partner
973-852-8379
amiliambro@frierlevitt.com
Brandon S. Zarsky
Partner
973-852-8398
bzarsky@frierlevitt.com
